Improving adherence in osteoporosis: A new management algorithm for the patient with osteoporosis

Gianluca Baio, Mario Barbagallo, Giovanni D'Avola, Andrea Di Luccio, Gian Luca Di Tanna, Paolo Falaschi, Giovanni Iolascon, Nazzarena Malavolta, Federico Robbiati, Fabio Massimo Ulivieri

Research output: Contribution to journalArticle

Abstract

Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered: We review available data and propose a new approach to improve adherence to osteoporosis therapy in clinical practice. We present the current evidence and personal experience from a group of Italian osteoporosis experts. Expert opinion: To improve adherence, we propose a multifaceted approach, which includes the Triad Model suggested by the World Health Organization, direct observed therapy and the use of drugs with longer administration intervals, e.g., zoledronic acid. The integration of these strategies may provide the basis for a marked increase in adherence to osteoporosis therapy, and improved clinical outcomes in a real-life scenario.

Original languageEnglish
Pages (from-to)257-268
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume12
Issue number2
DOIs
Publication statusPublished - Feb 2011

Fingerprint

Osteoporosis
zoledronic acid
Diphosphonates
Expert Testimony
Therapeutics
Bone Resorption
Bone Density
Clinical Trials
Drug Therapy
Incidence

Keywords

  • Adherence
  • Bisphosphonates
  • Bone density
  • Medication possession ratio
  • Osteoporosis
  • Treatment algorithm

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Improving adherence in osteoporosis : A new management algorithm for the patient with osteoporosis. / Baio, Gianluca; Barbagallo, Mario; D'Avola, Giovanni; Di Luccio, Andrea; Di Tanna, Gian Luca; Falaschi, Paolo; Iolascon, Giovanni; Malavolta, Nazzarena; Robbiati, Federico; Ulivieri, Fabio Massimo.

In: Expert Opinion on Pharmacotherapy, Vol. 12, No. 2, 02.2011, p. 257-268.

Research output: Contribution to journalArticle

Baio, G, Barbagallo, M, D'Avola, G, Di Luccio, A, Di Tanna, GL, Falaschi, P, Iolascon, G, Malavolta, N, Robbiati, F & Ulivieri, FM 2011, 'Improving adherence in osteoporosis: A new management algorithm for the patient with osteoporosis', Expert Opinion on Pharmacotherapy, vol. 12, no. 2, pp. 257-268. https://doi.org/10.1517/14656566.2011.537259
Baio, Gianluca ; Barbagallo, Mario ; D'Avola, Giovanni ; Di Luccio, Andrea ; Di Tanna, Gian Luca ; Falaschi, Paolo ; Iolascon, Giovanni ; Malavolta, Nazzarena ; Robbiati, Federico ; Ulivieri, Fabio Massimo. / Improving adherence in osteoporosis : A new management algorithm for the patient with osteoporosis. In: Expert Opinion on Pharmacotherapy. 2011 ; Vol. 12, No. 2. pp. 257-268.
@article{d3c6836dbd7b4db989c0e818cf3cbbe8,
title = "Improving adherence in osteoporosis: A new management algorithm for the patient with osteoporosis",
abstract = "Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered: We review available data and propose a new approach to improve adherence to osteoporosis therapy in clinical practice. We present the current evidence and personal experience from a group of Italian osteoporosis experts. Expert opinion: To improve adherence, we propose a multifaceted approach, which includes the Triad Model suggested by the World Health Organization, direct observed therapy and the use of drugs with longer administration intervals, e.g., zoledronic acid. The integration of these strategies may provide the basis for a marked increase in adherence to osteoporosis therapy, and improved clinical outcomes in a real-life scenario.",
keywords = "Adherence, Bisphosphonates, Bone density, Medication possession ratio, Osteoporosis, Treatment algorithm",
author = "Gianluca Baio and Mario Barbagallo and Giovanni D'Avola and {Di Luccio}, Andrea and {Di Tanna}, {Gian Luca} and Paolo Falaschi and Giovanni Iolascon and Nazzarena Malavolta and Federico Robbiati and Ulivieri, {Fabio Massimo}",
year = "2011",
month = "2",
doi = "10.1517/14656566.2011.537259",
language = "English",
volume = "12",
pages = "257--268",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Improving adherence in osteoporosis

T2 - A new management algorithm for the patient with osteoporosis

AU - Baio, Gianluca

AU - Barbagallo, Mario

AU - D'Avola, Giovanni

AU - Di Luccio, Andrea

AU - Di Tanna, Gian Luca

AU - Falaschi, Paolo

AU - Iolascon, Giovanni

AU - Malavolta, Nazzarena

AU - Robbiati, Federico

AU - Ulivieri, Fabio Massimo

PY - 2011/2

Y1 - 2011/2

N2 - Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered: We review available data and propose a new approach to improve adherence to osteoporosis therapy in clinical practice. We present the current evidence and personal experience from a group of Italian osteoporosis experts. Expert opinion: To improve adherence, we propose a multifaceted approach, which includes the Triad Model suggested by the World Health Organization, direct observed therapy and the use of drugs with longer administration intervals, e.g., zoledronic acid. The integration of these strategies may provide the basis for a marked increase in adherence to osteoporosis therapy, and improved clinical outcomes in a real-life scenario.

AB - Introduction: Bisphosphonates are the first-choice treatment for osteoporosis. They effectively increase bone mineral density, reduce markers of bone resorption, and lower the incidence of new fractures in patients with osteoporosis-related fracture. However, the efficacy observed in clinical trials may not be realized in a real-life setting, partly due to poor adherence to therapy, with a significant worsening of clinical outcomes. Several issues contribute to poor adherence to osteoporosis medication, including inconvenient dosing regimens and concerns about possible adverse events. Although strategies to improve adherence have been investigated, new approaches are required. Areas covered: We review available data and propose a new approach to improve adherence to osteoporosis therapy in clinical practice. We present the current evidence and personal experience from a group of Italian osteoporosis experts. Expert opinion: To improve adherence, we propose a multifaceted approach, which includes the Triad Model suggested by the World Health Organization, direct observed therapy and the use of drugs with longer administration intervals, e.g., zoledronic acid. The integration of these strategies may provide the basis for a marked increase in adherence to osteoporosis therapy, and improved clinical outcomes in a real-life scenario.

KW - Adherence

KW - Bisphosphonates

KW - Bone density

KW - Medication possession ratio

KW - Osteoporosis

KW - Treatment algorithm

UR - http://www.scopus.com/inward/record.url?scp=78651467821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78651467821&partnerID=8YFLogxK

U2 - 10.1517/14656566.2011.537259

DO - 10.1517/14656566.2011.537259

M3 - Article

C2 - 21226636

AN - SCOPUS:78651467821

VL - 12

SP - 257

EP - 268

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -